Minerva Neurosciences, Inc. Shareholders' Equity
Minerva Neurosciences, Inc. (NERV) had Shareholders' Equity of -$213.30 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-07
- 2026-06-30: Stockholders' Equity Attributable to Parent -$213.30M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$254.01M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$140.75M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$34.58M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$213.30M 10-Q · filed 2026-08-07 |
| 2026-03-31 | -$254.01M 10-Q · filed 2026-08-07 |
| 2025-12-31 | -$140.75M 10-Q · filed 2026-08-07 |
| 2025-09-30 | -$34.58M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$32.11M 10-Q · filed 2026-08-07 |
| 2025-03-31 | -$29.15M 10-Q · filed 2026-08-07 |
| 2024-12-31 | -$25.69M 10-Q · filed 2026-08-07 |
| 2024-09-30 | -$21.67M 10-Q · filed 2025-11-05 |
| 2024-06-30 | -$44.49M 10-Q · filed 2025-11-05 |
| 2024-03-31 | -$36.59M 10-Q · filed 2025-11-05 |
| 2023-12-31 | -$28.46M 10-K · filed 2026-03-11 |
| 2023-09-30 | -$20.05M 10-Q · filed 2024-11-05 |
| 2023-06-30 | -$12.51M 10-Q · filed 2024-11-05 |
| 2023-03-31 | -$26.62M 10-Q · filed 2024-11-05 |
| 2022-12-31 | -$20.02M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$14.25M 10-Q · filed 2023-11-07 |
| 2022-06-30 | -$8.38M 10-Q · filed 2023-11-07 |
| 2022-03-31 | -$736.13K 10-Q · filed 2023-11-07 |
| 2021-12-31 | $7.98M 10-K · filed 2024-02-22 |
| 2021-09-30 | $28.08M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $36.17M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $45.37M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $52.66M 10-K · filed 2023-03-08 |
| 2020-09-30 | $58.02M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $56.94M 10-Q · filed 2021-11-08 |
| 2020-03-31 | $18.62M 10-Q · filed 2021-11-08 |
| 2019-12-31 | $27.78M 10-K · filed 2022-03-01 |
| 2019-09-30 | $55.53M 10-Q · filed 2020-11-02 |
| 2019-06-30 | $67.27M 10-Q · filed 2020-11-02 |
| 2019-03-31 | $77.42M 10-Q · filed 2020-11-02 |
| 2018-12-31 | $90.26M 10-K · filed 2021-03-08 |
| 2018-09-30 | $101.39M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $110.66M 10-Q · filed 2019-11-04 |
| 2018-03-31 | $121.29M 10-Q · filed 2019-11-04 |
| 2017-12-31 | $131.60M 10-K · filed 2020-03-09 |
| 2017-09-30 | $130.18M 10-Q · filed 2018-11-05 |
| 2017-06-30 | $98.03M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $106.29M 10-Q · filed 2018-05-03 |
| 2016-12-31 | $105.98M 10-K · filed 2019-03-12 |
| 2016-09-30 | $113.14M 10-Q · filed 2017-11-06 |
| 2016-06-30 | $120.61M 10-Q · filed 2017-08-03 |
| 2016-03-31 | $66.65M 10-Q · filed 2017-05-04 |
| 2015-12-31 | $55.32M 10-K · filed 2018-03-12 |
| 2015-09-30 | $63.07M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $68.38M 10-Q · filed 2016-08-04 |
| 2015-03-31 | $74.44M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $51.50M 10-K · filed 2018-03-12 |
| 2014-09-30 | $56.72M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $29.23M 10-Q · filed 2014-08-07 |
| 2013-12-31 | $20.18M 10-K · filed 2017-03-13 |
| 2012-12-31 | $19.02K 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |